| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | BRD-A94377914 | CTRPv2 | pan-cancer | AAC | -0.006 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0042 | 0.9 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.0059 | 0.9 |
| mRNA | BRD-K92856060 | CTRPv2 | pan-cancer | AAC | 0.0043 | 0.9 |
| mRNA | ML083 | CTRPv2 | pan-cancer | AAC | -0.0046 | 0.9 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.9 |